Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT3 | O60678 | 1/20 | 0.48 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.47 |
| ▸ | EGFR | P00533 | 1/20 | 0.46 |
| ▸ | HTR2C | P28335 | 6/20 | 0.42 |
| ▸ | MCHR1 | Q99705 | 6/20 | 0.42 |
| ▸ | NCF1 | P14598 | 1/20 | 0.42 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.40 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.40 |
| ▸ | ACP1 | P24666 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24124775 | 1.00 | PRMT3 (0.48) | PRMT3HRH3EGFRHTR2CMCHR1 | |
| SCHEMBL25920547 | 0.83 | PRMT3 (0.46) | PRMT3HRH3EGFRKDM4EALDH1A1 | |
| SCHEMBL25920269 | 0.81 | MCHR1 (0.65) | PRMT3HTR2CMCHR1ALDH1A1 | |
| SCHEMBL24124251 | 0.79 | EGFR (0.54) | EGFRKDM4EALDH1A1 | |
| SCHEMBL24125008 | 0.76 | EGFR (0.42) | PRMT3EGFRKDM4EALDH1A1 | |
| SCHEMBL27319515 | 0.74 | CHKA (0.50) | HRH3EGFRKDM4EALDH1A1 | |
| SCHEMBL25920273 | 0.74 | PPARA (0.51) | EGFRKDM4EALDH1A1 | |
| SCHEMBL24124769 | 0.73 | F2 (0.53) | EGFRKDM4EALDH1A1 | |
| SCHEMBL24124319 | 0.72 | F2 (0.58) | EGFRKDM4EALDH1A1 | |
| SCHEMBL24125108 | 0.71 | EGFR (0.48) | HRH3EGFRKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230242496-A1 | SOX11 INHIBITORS FOR TREATING MANTLE CELL LYMPHOMA | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2023-08-03 | — | — | US | disclosed |
| US-20230242496-A1 | SOX11 INHIBITORS FOR TREATING MANTLE CELL LYMPHOMA | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2023-08-03 | — | — | US | disclosed |
| WO-2021257544-A1 | SOX11 INHIBITORS FOR TREATING MANTLE CELL LYMPHOMA | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2021-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230242496-A1 | SOX11 INHIBITORS FOR TREATING MANTLE CELL LYMPHOMA | BCL6, SOX18, BCL3 | PRMT3 931/4885HRH3 2990/4885EGFR 1566/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.